Company Analysis
Sign in

ProKidney Corp. (PROK)

Nasdaq: PROK · Biological Products, (No Diagnostic Substances) · Winston-Salem, NC · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.3
◀ Past 5.6● Present 3.6▶ Future 6.5
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 18, 2026Mar 17, 2025Mar 22, 2024Mar 28, 2023Mar 24, 2022·
Revenue893,00076,00000··
Research and development114,123,000127,668,000106,707,00082,070,00046,255,00021,042,000
General and administrative51,777,00056,084,00044,815,00070,937,0008,855,0005,982,000
Total operating expenses165,900,000183,752,000151,522,000153,007,00055,110,00027,024,000
Operating income-165,007,000-183,676,000-151,522,000-153,007,000-55,110,000-27,024,000
Interest expense4,0009,00012,000215,00000
Interest and investment income13,813,00019,752,00022,083,0005,983,0002,00043,000
Income before income taxes-151,198,000-163,933,000-129,451,000-147,239,000-55,108,000-26,981,000
Income tax expense414,000-598,0005,996,000896,00038,000-232,000
Net income including non-controlling interests-151,612,000-163,335,000-135,447,000-148,135,000-55,146,000-26,749,000
Net income-68,986,000-61,186,000-35,468,000·-55,146,000·
Earnings per share, basic···-0.23··
Earnings per share, diluted···-0.23··
Weighted average shares, basic···61,540,231··
Weighted average shares, diluted···61,540,231··
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeNonoperating
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton PROK · research, not advice